Disubstituted pyrazole compounds
The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
1. A compound of the formula:
wherein
X is N, or C substituted with CN;
R 1 is selected from: H,
R 2 and R 3 are both H, or one is H and the other is OH;
R 4 , R 5 , R 6 , R 7 and R 9 are independently H or CH 3 ;
R 8 is H, CH 3 , CH 2 CH 2 OH, C(═O)CH 2 NH 2 , or C(═O)CH 3 ; and
R 10 is OH or NH 2 ;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein R 1 is selected from:
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 , wherein X is N, or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 , wherein X is C substituted with CN, or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
7. The compound, or pharmaceutically acceptable salt thereof, according to claim 6 , which is a succinate salt.
8. A method of treating type 2 diabetes mellitus in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
9. A method of treating heart failure in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
10. A method of treating diabetic kidney disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
11. A method of treating non-alcoholic steatohepatitis in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
12. A method of treating type 2 diabetes mellitus in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6 ,
or a pharmaceutically acceptable salt thereof.
13. A method of treating heart failure in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6 ,
or a pharmaceutically acceptable salt thereof.
14. A method of treating diabetic kidney disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6 ,
or a pharmaceutically acceptable salt thereof.
15. A method of treating non-alcoholic steatohepatitis in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6 ,
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition, comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients.
17. A process for preparing a pharmaceutical composition, comprising admixing a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients.